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RESEARCH ARTICLE Open Access
Targeted high-throughput sequencing of
candidate genes for chronic obstructive
pulmonary disease
Hans Matsson1,2* , Cilla Söderhäll1,2, Elisabet Einarsdottir1,3, Maxime Lamontagne4, Sanna Gudmundsson5,
Helena Backman6, Anne Lindberg7, Eva Rönmark6, Juha Kere1,3, Don Sin8, Dirkje S. Postma9, Yohan Bossé4,10,
Bo Lundbäck11 and Joakim Klar5
Abstract
Background: Reduced lung function in patients with chronic obstructive pulmonary disease (COPD) is likely due to
both environmental and genetic factors. We report here a targeted high-throughput DNA sequencing approach to
identify new and previously known genetic variants in a set of candidate genes for COPD.
Methods: Exons in 22 genes implicated in lung development as well as 61 genes and 10 genomic regions
previously associated with COPD were sequenced using individual DNA samples from 68 cases with moderate or
severe COPD and 66 controls matched for age, gender and smoking. Cases and controls were selected from the
Obstructive Lung Disease in Northern Sweden (OLIN) studies.
Results: In total, 37 genetic variants showed association with COPD (p < 0.05, uncorrected). Several variants
previously discovered to be associated with COPD from genetic genome-wide analysis studies were replicated
using our sample. Two high-risk variants were followed-up for functional characterization in a large eQTL mapping
study of 1,111 human lung specimens. The C allele of a synonymous variant, rs8040868, predicting a p.(S45=) in the
gene for cholinergic receptor nicotinic alpha 3 (CHRNA3) was associated with COPD (p = 8.8 x 10−3). This association
remained (p = 0.003 and OR = 1.4, 95 % CI 1.1-1.7) when analysing all available cases and controls in OLIN (n = 1,534).
The rs8040868 variant is in linkage disequilibrium with rs16969968 previously associated with COPD and altered
expression of the CHRNA5 gene. A follow-up analysis for detection of expression quantitative trait loci revealed that
rs8040868-C was found to be significantly associated with a decreased expression of the nearby gene cholinergic
receptor, nicotinic, alpha 5 (CHRNA5) in lung tissue.
Conclusion: Our data replicate previous result suggesting CHRNA5 as a candidate gene for COPD and rs8040868 as a
risk variant for the development of COPD in the Swedish population.
Keywords: COPD, Sequencing, eQTL, Association, Lung development, CHRNA5
Background
Chronic obstructive pulmonary disease (COPD), charac-
terised by a persistent airflow obstruction [1], is a life-
threatening disease accounting for 6 % of all deaths
globally in 2012 [2]. The development of the disease is in-
fluenced by environmental determinants, most commonly
cigarette smoking, genetic risk factors and possible genetic
protective factors [3]. Candidate gene association studies
have suggested several potential COPD susceptibility
genes, and genome-wide association studies (GWAS) have
identified multiple COPD susceptibility loci [4]. However,
genetic mapping in families with high penetrance for a
disease gene variant can be helpful in pinpointing new
susceptibility genes even for multifactorial traits. Recently,
we reported mutations in the gene for fibroblast growth
factor 10 (FGF10) involved in lung development, as a pos-
sible cause of COPD in families from Sweden [5]. Hence,
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a monogenic form of COPD could result from muta-
tions in FGF10. To date, the only other known mono-
genic form of COPD is alpha 1-antitrypsin deficiency
caused by disruption of the alpha-1-antiproteinase
(SERPINA1) gene [6].
Typically in GWAS, common polymorphisms are
tested for association. In this study, we provide an alter-
native approach with the aim to perform an in-depth
analysis of exons of candidate genes for COPD by using
high-throughput sequencing. This allowed us to detect
the full spectrum of single nucleotide variation at any
frequency in selected genomic regions and to also cap-
ture variants with a potential functional effect on gene
expression levels. We show here that targeted high
throughput sequencing using a well-defined population-
based case–control sample can i) assess the impact of
common variants in genes important for lung develop-
ment, and ii) test genetic variants in a large set of candi-
date genes and genomic regions for association with
COPD. To accomplish this we captured and sequenced
22 genes implicated in lung development as well as 61
genes and 10 genomic regions previously associated
with COPD. The sample used here is comprised of
cases and controls from The Obstructive Lung Disease
in Northern Sweden (OLIN) studies. The population in
northern Sweden, an admixture of three different eth-
nic groups (Swedes, Finns and Saami), showed a dra-
matic growth of population size since the 18th century
from a relatively small founder population [7]. This re-
sulted in founder effects that significantly reduced the
heterogeneity of this population, making it suitable for
genetic association studies of multifactorial phenotypes,
such as COPD [8].
This study assessed Swedish COPD cases and controls
and assessed detected variants in candidate genes for
association with COPD. We replicated a previous de-
scribed association signal in CHRNA3, which also asso-
ciated with lower CHRNA5 gene expression. The DNA
capture design and targeted sequencing used here show
potential to detect known single nucleotide variants in
association with COPD with the additional potential to
also detect low-frequent variants. The result presented
here using the relative limited sample size could be rep-
licated using our targeted capture design in larger sam-
ples from different populations.
Methods
Patient material and ethics statement
The OLIN studies are an on-going research program fo-
cused on asthma, allergy and COPD. It started 30 years
ago [9] and now involves more than 50,000 subjects
from northern Sweden. Within OLIN, a COPD-cohort
was identified at re-examination of several cohorts in
2002–2004 [10]. At recruitment, COPD (n = 993) was
defined using the fixed ratio of FEV1 / FVC < 0.70
(forced expiratory volume in 1 s / forced vital capacity).
When calculating the ratio FEV1 / FVC, the highest
values of FEV1 and the highest value of forced vital cap-
acity (FVC) or slow vital capacity (SVC) were used. This
has support in the GOLD documents [1] and is ac-
knowledged in the recent ERS task force guidelines for
epidemiological studies on COPD [11]. An age and gen-
der matched control population (n = 993) without ob-
structive lung function impairment was also recruited
[10]. Since 2005 the OLIN COPD cohort with corre-
sponding controls is followed up annually with a basic
program including spirometry and interviews regarding
symptoms and morbidity [12]. We initially selected 96
COPD cases (18 non-smokers, 43 former smokers and
35 smokers) from those who had an FEV1 < 80 % of pre-
dicted value in 2005 and either FEV1 / FVC < LLN
(lower limit of normal) in 2010 or were rapid decliners
with an annual FEV1 decline of ≥ 60 ml between 2005
and 2010. We also identified a set of 96 age- and
gender-matched controls (33 smokers and 63 former
smokers) with normal lung function. These 96 cases and
96 controls are henceforth termed the OLIN discovery
sample (Table 1). Furthermore, we defined an OLIN rep-
lication sample consisting of individuals from the OLIN
COPD study for which DNA was available (n = 1,534).
From this group we classified individuals as cases when
FEV1 / FVC was lower than LLN in 2010, or if they had
a yearly FEV1 decline from 2005 to 2010 of at least
60 ml (n = 256). The remaining individuals were used as
Table 1 Pulmonary function in patients and controls




Cases 2.69 (0.95) 2.87 (0.81) 3.79 (0.81) 1.50 (0.59) 2.01 (0.55) 2.78 (0.61) 53 (14) 0.56 (0.11) 0.62 (0.03) 0.73 (0.03)
Controls 3.96 (0.90) 2.77 (0.77) 3.83 (0.77) 3.11 (0.69) 2.05 (0.55) 2.82 (0.59) 110 (9) 0.79 (0.05) 0.62 (0.03) 0.74 (0.03)
P value 6.3 × 10−18 0.42 0.75 4.0 × 10−41 0.62 0.58 2.5 × 10−81 2.5 × 10−45 0.24 0.23
Values in parenthesis denote standard deviations. FVC Forced vital capacity, LLN Lower limit of normal, FVC pred, predicted FVC based on age, gender and length
in the population. FEV1 Forced expiratory volume in 1 s, FEV1 Predicted FEV1 based on age, gender and length in the population, FEV1%pred, FEV1 Divided by
predicted FEV1 in the population, FEV1 / FVC ratio when investigated the fifth year of the evaluations. The lower limit of normal (LLN) values where calculated by
subtracting 1.645 × RSD (residual standard deviation) from the predicted value (pred). FEV1%pred is the measured FEV1 value divided by the predicted value
(i.e., FEV1 / FEV1pred). P values are calculated using two-sided Student’s t-test assuming equal variance. SD Standard deviation
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a reference group (n = 1,278). The physiological pa-
rameters for the OLIN replication sample included
average age (cases 64 years, SD 11; controls 66 years,
SD 11; P = 0.0012), gender (cases 123 females, 133
males; controls 569 females, 709 males; P = 0.30),
smoking habits (cases 11 pack/year, SD 15; controls 23
pack/year, SD 17; P = 4.2 × 10−9), weight (cases 73 kg,
SD 15; controls 77 kg, SD 14; P = 1.2 × 10−4) and height
(cases 168 cm, SD 9; controls 168 cm, SD 10; P = 0.8). The
phenotype description of this sample included measures
of FVC (cases 3.29, SD 1.01; controls 3.50, SD 1. 03;
P = 0.0031), FEV1 (cases 1.90, SD 0.67; controls 2.64,
SD 0.81; P = 9.5 × 10−43) and FEV1% of predicted
values (cases 67 %, SD 17 %; controls 95 % SD 16 %;
P = 5.3 × 10−73), as well as the FEV1/FVC ratio (cases
0.57, SD 0.08; controls 0.75, SD 0.07; P = 2.0 × 10−108)
when investigated the fifth year of the evaluations.
For description of individual reference values, see
Additional file 1.
P values for differences in parameters between cases
and controls were calculated using two-sided Stu-
dent’s t-tests, assuming equal variance. The ethics
board of Umeå University (Dnr 04-045 M, supple-
ment approved 2005-06-13) approved the use of indi-
vidual phenotypic data and DNA samples for genetic
research.
Sequencing and quality controls
In total 22 genes implicated in lung development, 61 genes
and 10 genomic regions previously associated with COPD
(Additional files 1 and 2), were investigated using targeted
sequencing of captured genomic regions (HaloPlex Proto-
col Version A, Agilent Technologies, Santa Clara, CA). Re-
gions of 1.5 kb of genomic sequence, including specific
intergenic polymorphisms, was also included in the design.
The regions of interest (ROI) were designed to target all
known exons of major/known transcripts and at least 20
base pairs (bp) of intronic sequences flanking each exon.
The sequence capture design included 953 target regions
spanning 204.384 bp with 95.9 % (196.066 bp) coverage an
average. Captured genomic regions were subjected to high
throughput paired-end (100 bp read module) sequencing
(HiSeq2000, Illumina, San Diego, CA) at the Science for
Life Laboratory in Uppsala, Sweden. Sequence reads were
aligned to the hg19 reference genome and single nucleo-
tide variants (SNVs) were called using GATK Unified
Genotyper (GATK bundle v.2.2) [13]. Next, we enriched
for high quality SNVs by removing SNVs with low confi-
dence (QD< 1.5), Phred scaled quality score (<50) and
SNVs within SNV clusters. These high quality variants are
henceforth referred to as ‘variants’. We also removed indi-
vidual cases and controls with sequencing read depth con-
sistently < 10 reads. The strategy for filtering and quality
controls are illustrated in Fig. 1.
Statistical analyses
Test for genetic association and genetic effect was per-
formed for each predicted variant separately using the
discovery sample. In addition, rs8040868 and rs11728716
were tested for association using the available OLIN
sample (replication sample) as, according to RegulomeDB,
these two markers present with potential functional effects
on gene regulation (Table 2). Tests for allelic association
of individual variants with COPD were performed using
the Fisher’s exact test. Results were considered statistically
significant when p < 0.05. No adjustment for multiple
testing was performed in these analyses. Effect size was
measured using odds-ratios (OR) with 95 % confidence
intervals (CI).
Visualization SNPs associated with COPD located in
the CHRNA3/5 region was made using LocusZoom v1.1
[14] available on http://locuszoom.sph.umich.edu/locus
zoom/. RefSeq gene/transcript case–control tests for ag-
gregation of genetic variants in the targeted genomic re-
gions were performed using PLINK/SEQ v0.1 [15]. Tests
were divided into an analysis of rare variants with minor
allele frequency (MAF) < 5 % or common variants
(MAF ≥ 5 %). The UNIQ test, which identifies unique
risk alleles, was utilized using default parameters to
count the total number of alleles found only in cases
(risk variants). Similarly, the SKAT burden tests,
which assesses excess of rare alleles in cases compared
to controls, was also utilized. Since both UNIQ and
SKAT burden are 1-sided tests, we also swapped the
phenotype information and analyzed the effects in
both directions (excess of alleles in cases or controls)
separately to capture evidence of both risk and pro-
tective alleles. Due to the matched design of the case
and control groups no covariate adjustments (age, sex,
pack-years) were performed in analysis using the dis-
covery sample.
Fig. 1 Flow chart of the strategy for variant calling, quality control
and association tests. QC = quality control
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Linkage disequilibrium information of associated vari-
ants was extracted from genotypes from the sequencing
analysis using Haploview 4.2 [16].
Functional analysis of associated variants
To study the possible effect of associated variants on gene
expression, we used information from RegulomeDB, a
Table 2 Associated genetic variants in the discovery sample set (n = 96 cases and n = 96 controls)
Chr Pos (bp) SNP rs ID Alt Ref F c (%) F p (%) OR (95 % CI) P value Gene Coding RG score ExAc Eur
frequencya
CADD_PHREDb
1 110230569 72989301 G A 10.0 22.1 2.5 (1.0-6.2) 0.038 GSTM1 4 0.24 NA
1 110233057 111436983 C T 11.6 26.7 2.8 (1.2-6.2) 0.013 GSTM1 7 0.24 NA
2 216991935 12694384 A C 29.4 17.9 0.5 (0.3-0.9) 0.04 XRCC5 5 NA NA
2 218669225 61741262 C T 13.6 0 NA 0.027 TNS1 p.(Asp1722Ser) 4 0.13 12.49
2 218746990 2303381 T A 7.7 1.5 0.2 (0.0-0.9) 0.019 TNS1 6 NA NA
3 55520778 566926 T G 39.2 25.0 0.5 (0.3-0.9) 0.017 WNT5A 3a NA NA
4 106638697 72671840 G A 2.3 11.4 5.3 (1.5-18.9) 5.8 × 10−3 GSTCD 6 NA NA
4 106647679 72671858 T C 3.0 10.5 3.7 (1.2-11.7) 0.026 GSTCD 7 NA NA
4 106755996 11728716 A G 3.4 21.0 7.4 (2.5-22.5) 6.5 × 10−5 GSTCD 1f NA NA
5 58284208 3805557 C T 22.0 11.9 0.5 (0.2-0.9) 0.034 PDE4D 7 NA NA
5 58284283 3805556 G A 22.0 11.8 0.5 (0.2-0.9) 0.033 PDE4D 6 0.84 NA
5 58286625 1553114 C T 22.0 11.8 0.5 (0.2-0.9) 0.033 PDE4D 7 0.84 NA
5 141993867 17223611 T C 10.6 3.0 0.3 (0.1-0.8) 0.025 FGF1 5 NA NA
6 142703137 2143390 T C 2.9 19.2 7.9 (1.6-37.6) 4.5 × 10−3 GPR126 p.(Asp373=) 7 0.12 NA
6 151197501 9322290 C T 17.4 9.0 0.5 (0.2-1.0) 0.047 MTHFD1L 5 NA NA
6 151206894 147872265 T C 7.6 2.2 0.3 (0.1-1.0) 0.049 MTHFD1L 7 0.002 NA
6 151263456 803451 A G 41.8 55.7 1.8 (1.1-2.9) 0.04 MTHFD1L 7 NA NA
6 151264132 803448 T C 37.9 50.7 1.7 (1.0-2.7) 0.037 MTHFD1L 6 NA NA
6 152183551 1643821 A G 25.8 39.0 1.8 (1.1-3.1) 0.026 ESR1 6 NA NA
8 42552530 41272375 C G 1.5 6.9 4.8 (1.0-22.8) 0.034 CHRNB3 5 NA NA
9 98239503 3780573 A G 18.3 8.7 0.4 (0.2-0.9) 0.041 PTCH1 5 NA NA
10 81706281 6413520 G A 0.8 5.9 8.2 (1.0-66.4) 0.036 SFTPD p.(Ser45=) 5 0.07 NA
10 123358096 41301039 G C 25.0 2.8 0.1 (0.0-0.7) 0.017 FGFR2 4 NA NA
11 102738499 632009 T C 29.6 50.8 2.5 (1.5-4.1) 6.7 × 10−4 MMP12 7 NA NA
12 23737566 11046992 A G 21.2 33.1 1.8 (1.1-3.2) 0.039 SOX5 6 NA NA
12 110224916 60258652 T C 2.4 10.5 4.7 (1.0-22.9) 0.05 TRPV4 5 NA NA
12 110224922 1861810 A C 36.6 53.8 2.0 (1.1-3.8) 0.04 TRPV4 5 NA NA
12 110232032 59870578 A G 7.8 1.6 0.2 (0.0-0.9) 0.034 TRPV4 4 NA NA
12 110232034 59940634 T G 7.8 1.6 0.2 (0.0-0.9) 0.034 TRPV4 4 NA NA
15 71434029 2004101 A T 0.8 5.6 7.5 (0.9-61.6) 0.035 THSD4 7 NA NA
15 78790189 2292115 G A 4.8 0 NA 0.03 IREB2 7 NA NA
15 78911181 8040868 C T 31.8 47.8 2.0 (1.2-3.2) 8.8 × 10−3 CHRNA3 p.(Val53=) 1f 0.41 NA
16 16130514 903880 A C 15.9 27.2 2.0 (1.1-3.6) 0.027 ABCC1 4 NA NA
16 16205741 9673292 C G 4.5 0 NA 0.013 ABCC1 6 NA NA
16 16230290 212087 A G 38.6 52.2 1.7 (1.1-2.8) 0.028 ABCC1 5 0.44 NA
16 16235366 113328089 A G 6.9 1.5 0.2 (0.0-1.0) 0.034 ABCC1 5 NA NA
20 15967390 41275442 T C 9.1 17.7 2.1 (1.0-4.5) 0.049 MACROD2 p.(Thr100Met) 4 0.18 3.98
Alt, non-reference allele. Ref, reference allele, OR Odds ratio with 95 % confidence intervals, F c Frequency in controls, F p Frequency in cases (patients), RG Score,
RegulomeDB score, NA Not available
aNon-Finnish European allele frequency extracted from ExAc v.0.3.1
bThe “PHRED-scaled” CADD score based on ranks of all SNV in the hg19 genome reference
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database that combines ENCODE data sets (chromatin
immunoprecipitation sequencing (ChIP-seq) peaks,
DNase I hypersensitivity peaks, DNase I footprints) with
additional data sources (ChIP-seq data from the NCBI Se-
quence Read Archive, conserved motifs, expression quan-
titative trait loci (eQTL), and experimentally validated
functional variants) [17]. A scoring system is based on the
confidence of the functionality of variants, a lower score
corresponding to stronger confidence. Subcategories are
used to denote additional functional annotations. Com-
bined Annotation Dependent Depletion (CADD) scores
were used to assess potential structural and functional ef-
fect of associated nonsynonymous variants [18].
Lung expression quantitative trait loci analyses
The existence of expression quantitative trait loci
(eQTLs) was investigated as previously described using
genotyping and gene expression data from 1,111 patients
who underwent lung surgery at one of three sites, Laval
University (discovery sample), University of British
Columbia, and University of Groningen (replication
sample sets) (referred to as Laval, UBC, and Groningen)
[19, 20]. The eQTL data is derived from non-tumour
lung parenchymal samples and expression data were
adjusted for age, gender, and smoking status. Estimated
P-values for each region were Bonferroni-corrected for
multiple testing based on the number of SNPs and probe
sets (number of SNPs x number of probe sets) and were
considered significant if corrected p < 0.05.
SNP genotyping for validation of rs11728716 and
rs8040868
Individuals from the OLIN replication sample (n = 1,534)
were genotyped for the rs11728716 and rs8040868 vari-
ants (99.2 % and 99.8 % success rate, respectively) at the
Uppsala Genome Center (Uppsala, Sweden) using com-
mercially available TaqMan assays (Life Technologies,
Carlsbad, CA). Assay conditions were according to manu-
facturer’s recommendations. Effect size was estimated by
comparing ORs with 95 % CI between cases and controls.
Furthermore, to assess smoking dependence, we measured
association and effect sizes also between the groups ‘non-
smokers’ and ‘ever smokers’, and between ‘current
smokers’ and ‘former smokers’.
Results
Selection of cases and controls for the discovery sample
The characteristics of each sample are listed in this sec-
tion as value ± standard deviation. Cases and controls
were matched for age (cases: 68 ± 10 years; controls:
66 ± 11 years; p = 0.15), gender (cases: 35 females, 61
males; controls: 31 females, 65 males; p = 0.65) and smok-
ing habits (cases: 26 ± 19 pack/year; controls: 28 ± 12
pack/year; p = 0.53). Both groups were also closely
matched for weight (cases: 76 ± 15 kg; controls: 77 ±
15 kg; p = 0.85) and height (cases: 169 ± 9 cm; controls:
169 ± 9 cm; p = 0.7). No non-smokers were included in
the control group to avoid false negative results. The cases
presented a significant reduction in lung function consist-
ent with moderate or severe COPD. This is illustrated by
a reduced FVC (cases: 2.69 ± 0.95 L; controls: 3.96 ±
0.90 L; p = 6.3 × 10−18), FEV1 (cases: 1.50 ± 0.59 L; con-
trols: 3.11 ± 0.69 L; p = 4.0 × 10−41) and FEV1% of pre-
dicted values (cases: 53 ± 14 %; controls: 110 ± 9 %;
p = 2.5 × 10−81), as well as the FEV1/FVC ratio (cases:
0.56 ± 0.11; controls: 0.79 ± 0.05; p = 2.5 × 10−45) when
investigated the fifth year of the evaluations (Table 1).
Test for association between genetic variants and COPD
We identified 2,151 SNVs after analysis of the sequenced
target regions. After variant and sample quality control
procedures, 1588 SNVs and 68 cases and 66 controls
were retained in the downstream analysis (Fig. 1). Out of
the 1588 variants, we identified 37 variants with signifi-
cantly different allele frequencies in cases and controls
(henceforth referred to as ‘associated variants’) (Table 2).
We initially detected two novel variants in the discovery
sample: GRCh37.p13, 5:g.157002804C >G in the ADAM19
gene and GRCh37.p13, 7:g.73477874C >A in ELN. How-
ever, using Sanger sequencing of the same sample we
excluded both variants, as they were monomorphic.
Three of the associated variants were shown to be
unique to controls including missense variant rs61741262
(p.Asn1722Ser) in TNS1. The most significantly associated
variants were all intronic (GSTCD, rs11728716, p = 6.5 ×
10−5, OR = 7.4 (2.5-22.5) and MMP12, rs632009, p = 6.7 ×
10−4, OR = 2.5 (1.5-4.1).
Although the majority of the associated variants were
intronic (or intergenic), five were protein-coding
(Table 2). Of these, two variants predicted amino-acid
substitutions (missense variants): p.(Thr100Met) in
MACROD2 and p.(Asn1722Ser) in TNS1 respectively.
The p.(Asn1722Ser) variant could be potential damaging
based on a relative high CADD score or 12.49. Of the
coding variants, we found that rs2143390, predicting a
p.(D373=) in GPR126 (p = 0.005, OR = 7.9 (1.6-37.6)),
rs6413520 in SFTPD (p.(Ser45=), p = 0.036, OR = 8.2
(1.0-66.4)), rs8040868 in CHRNA3 (p.(Val53=), p = 8.8 ×
10−3, OR = 2.0 (1.2-3.2)) and rs41275442 in MACROD2
(p.(Thr100Met), p = 0.049, OR = 2.1 (1.0-4.5)) conferred
moderate to high risk for COPD (Table 2).
We tested the presence of variants uniquely found in
cases or controls as well as gene burden tests in cases
against controls as specified in PLINK/SEQ v0.1 using
standard settings. We noted that the ADAM19, WNT2,
CHRNA5, NOS3 and PTCH1 genes all harbor rare vari-
ants (MAF < 5 %) uniquely found in cases (Additional
file 3). Conversely, the FGF8, CTNNB1 and HHIP genes
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contain rare variants uniquely found in the control
sample (Additional file 3). Neither gene burden ana-
lysis (SKAT) or analysis of rare alleles (MAF < 5 %)
yielded significant results. However, by performing a
joint analysis with only common alleles (MAF ≥ 5 %)
in target regions using SKAT, we showed a significant
gene burden for the genes GSTCD, FGF1, ELN and
ESR1 (Additional file 4).
Haplotypes and linkage disequilibrium
We identified five regions with associated variants in
pairwise LD (r2 > 0.7, D´ = 1.0). The regions were lo-
cated at the GSTM1 gene locus on chromosome 1
(rs72989301-rs111436983), GSTCD on chromosome 4
(rs72671840-rs72671858), PDE4D on chromosome 5
(rs3805557- rs3805556- rs1553114), MTHFDIL on
chromosome 6 (rs803451- rs803448) and TRPV4 on
chromosome 12 (rs59870578-rs59940634) (Additional
file 5). Furthermore, the variant rs8040868 on chromo-
some 15q21.1 is in pairwise LD (r2 = 0.76, D’ = 1.0) with
rs16969968, a nonsynonymous variant previously asso-
ciated with expression of the CHRNA5 gene [21]. The
rs16969968 variant was included in our capture design
but it did not reach significant association in the OLIN
discovery sample (OR 1.6; p = 0.07) (Additional file 6).
In silico analysis of predicted functions of associated
variants
According to RegulomeDB, all 37 associated variants
were located within known and predicted regulatory ele-
ments in intergenic regions (Table 2). We noted that a
variant in CHRNA3 (rs8040868) and a variant in GSTCD
(rs11728716) each showed a RegulomeDB score of “1f”,
denoting the presence of transcription binding site or
DNAse peak.
Lung eQTL results
According to RegulomeDB, the rs8040868 (CHRNA3)
and rs11728716 (GSTCD) variants could present with
potential functional effects on gene regulation. To deter-
mine if these variant could represent eQTL, we analysed
the genotypes and gene expression data in the discovery
sample (Laval) as well as replication samples (UBC and
Groningen). One of these variants, rs8040868:C > T, was
confirmed to be significantly associated with gene ex-
pression of the nearby gene CHRNA5 in all three data
sets, with the C allele (minor allele) associated with
lower CHRNA5 expression (Fig. 2 and Additional file 7).
Interestingly, we could also see a high correlation be-
tween rs8040868 and expression of an anti-sense tran-
script (AF147302) of unknown function from the
adjacent IREB2 gene region (data not shown). AF147302
is likely a result of strong bi-directional promoter activ-
ity in this region [22].
The rs8040868 variant is associated with COPD in the
OLIN replication sample
We also investigated pulmonary data from the replica-
tion sample (n = 1,534; cases = 256, controls = 1278).
Analysis using RegulomeDB predicted both rs11728716
and rs8040868 variants as being functional (score 1f for
both variants). We therefore selected these two variants
for genotyping in all available OLIN samples (n = 1,534).
The frequency of the rs8040868-C allele was 35 % in
the reference group (n = 1,278) and 42 % in the cases
(n = 256) resulting in a significant association (p = 0.003)
and an OR of 1.4 (95 % CI 1.1-1.7) for COPD. SweGen
variant frequency database reports a 39 % frequency of
rs8040868 in 1000 whole genomes representing a cross-
section of the Swedish population (https://swefreq.
nbis.se). The frequency of the homozygous rs8040868-CC
Fig. 2 CHRNA5 gene expression levels in the lungs according to genotype groups for rs8040868. The left y-axis represents standardised gene
expression levels in the lung with heterozygous genotype group set to zero. The x-axis represents the three genotyping groups, TT, CT and CC
(risk allele C), for the variant in (a) the discovery set (Laval) n = 408; P = 4.2 × 10−10, and the replication sets (b) UBC, n = 287; P = 2.31 × 10−7, and
(c) Groningen, n = 342; P = 1.5 × 10−6. The number of subjects per genotype group is indicated in parenthesis. The right y-axis shows the proportion
of the gene expression variance explained by the variant (black bar)
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genotype was 12 % in the reference group and significantly
higher (18 %) in the cases (p = 0.018). When comparing
smoking status using all genotyped individuals, no
significant difference in allele frequency between nei-
ther the groups ‘non-smokers’ (n = 589) and ‘ever
smokers’ (n = 943) (OR 1.1 95 % CI 1.0-1.7; p = 0.09)
nor between the groups ‘current smokers’ (n = 312)
and ‘former smokers’ (n = 631) (OR 1.2 95 % CI 1.0-
1.4; p = 0.11) was seen. The latter test was used to as-
sess nicotine dependency and aptitude for smoking
cessation under the assumption that a genetic variant
associated with these traits would be underrepresented
in a former smoking group as compared to a group of
current smokers, i.e., harder to quit smoking. The tests
for association with smoking must however be taken
with caution as the confidence intervals are wide and a
larger sample size would be needed for replication.
Analysis of rs11728716 using the OLIN replication
sample (n = 1,534) revealed no association with COPD
(p = 0.07; OR = 2.2). In order to test if rs11728716 is as-
sociated with severe COPD, we stratified the available
COPD cases based on severity and selected cases with
FEV1%pred < 40 % and FEV1/FVC < LLN. Our results
show a significant association (p = 0.017) between
rs11728716 and the group of severe COPD (n = 14).
The allele frequency of rs11728716-A was 10 % among
cases with severe COPD and 4 % in the controls.
Discussion and conclusion
Genetic variants influencing lung function in children
and adults may ultimately lead to the development of
COPD [23]. Since limited disease-specific therapy for
COPD is available, an improved knowledge of genetic
variants modulating the pathogenic mechanisms under-
lying COPD is greatly needed. We aimed here to identify
genetic variants within, or close to, the coding regions of
genes and loci previously associated with COPD, or in
genes involved in lung development. We opted for a
qualitative rather than a quantitative approach with the
selection of cases with moderate or severe COPD and
progressive decline in lung function. Furthermore, con-
trols were all smokers without COPD that, in our study
design, can aid the identification of potential protective
genetic variants and aid detection of genetic variants as-
sociated with severe COPD. When applying a Bonferroni
correction for the total number of variants detected, no
variants showed statistically significant association. We
did, however, identify several variants with a likely bio-
logical significance, as indicated by high effect sizes
(odds ratio), that we believe warrants further investiga-
tion in a larger sample. Furthermore, potential func-
tional effects of variants were investigated using data
from a large number of lung samples and we describe
here a COPD lung eQTL.
When comparing our association data with the lung
eQTL data (discovery data set from Laval University), we
could identify a variant associated with COPD that was also
associated with level of gene expression (Fig. 2). This vari-
ant, synonymous variant (rs8040868) in CHRNA3 on
chromosome 15, confers a risk for the development of
COPD in both our OLIN discovery sample with moderate
or severe COPD and our OLIN replication sample includ-
ing all available COPD cases and controls in OLIN (OR 1.4,
p = 0.003). In the lung eQTL data, we could see a correl-
ation of the C allele of rs8040868 with lower expression
levels of CHRNA5 (Fig. 2), and, to a lesser extent, also
CHRNA3 and PSMA4, which are located in close proximity
to CHRNA5. The α-nicotinic receptor (CHRNA3/5) gene
locus on chromosome 15q25.1 is associated with COPD,
lung cancer and peripheral arterial disease, as well as other
smoking related conditions [24, 25] and nicotine addiction
[26, 27]. Recently, the CHRNA3/5 locus was implicated in
all-cause mortality among smokers in a Finnish cohort [2].
The rs8040868-C allele associates with both reduced pul-
monary function and lung cancer [24, 25, 28, 29] and af-
fects DNA-methylation and transcription of CHRNA5 [30].
Furthermore, rs8040868 is also in LD with a nearby variant
(rs16969968) previously reported to be associated with ex-
pression levels of CHRNA5 in the lung [21]. The direction
of effect is the same for both SNPs, with the minor alleles
associated with reduced expression of CHRNA5. Also re-
cently, rs16969968 was found to be the most significantly
associated variant in an exome array analysis in a study in-
cluding more than 6,100 COPD cases and 6,000 control
subjects across five cohorts [31].
Several genetic variants showed association with
COPD in our population, but did not correlate with gene
expression levels in the lung, including previously identi-
fied variants in the genes glutathione S-transferase, c-
terminal domain containing (GSTCD), surfactant protein
D (SFTPD) and matrix metalloproteinase-12 (MMP12)
[32–36]. We identified a haplotype consisting of three
risk-conferring variants, rs72671840, rs72671858 and
rs11728716 (G-T-A haplotype), at the GSTCD gene
locus on chromosome 4q24. The variant rs11728716 has
previously been associated with lung function [32–34]
and is likely to affect the transcription of GSTCD. We
show here that rs11728716 was associated with severe
COPD using the OLIN replication sample. Although intri-
guing, due to the limited number of severe COPD cases
used in this study, this result needs further verification in
a larger sample. The other two variants (rs72671840 and
rs72671858) are of unknown function [37]. GSTCD en-
codes a glutathione S-transferase C-terminal domain pro-
tein involved in detoxification by catalysing conjugation of
glutathione to products of oxidative stress. We found as-
sociation between COPD and rs6413520, a synonymous
variant, p.(Ser45=), within SFTPD on chromosome
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10q22.3. This variant conferred a high risk (OR = 8.2) for
COPD in our study and has previously been reported to
be associated with COPD susceptibility [36]. SFTPD en-
codes surfactant protein D, of importance for the regula-
tion of oxidant production, inflammatory responses, and
apoptotic cell clearance in the lung [38]. We also identi-
fied rs632009, in the MMP12 gene on chromosome
11q22.3, to confer moderate risk. Matrix metalloprotein-
ases (MMPs) are involved in both tissue remodelling and
repair and several members of the MMP family have been
implicated in COPD pathology [35, 39, 40].
In this study, we also found association (uncorrected)
with novel susceptibility variants. Several variants in the
G-protein-coupled receptor 126 (GPR126) gene on
chromosome 6q24.1 have previously been associated
with FEV1 / FVC ratio [32]. GPR126 belongs to a super-
family of G protein-coupled receptors and is involved in
cell signalling and adhesion. Studies in mice show an
induction of Gpr126 expression between embryonic
day 7 and 11 with expression in the developing heart
and face as well as a high expression in the adult lung
[41]. We found significant association between a syn-
onymous variant in the GPR126 gene (rs2143390,
p.(Asp373=)) and COPD. The alternative T allele is
highly overrepresented in cases compared to controls
(p = 4.5 × 10−3, OR = 7.9).
We also focused our attention to the chromosome
4q31 locus upstream of HHIP, previously shown to be
associated with expression of the gene [20, 42]. The
HHIP upstream region belongs to one of the so far
strongest COPD association signals [43], but no associ-
ation could be seen in our case–control groups for any
upstream variants.
The sequencing approach allowed us to detect rare al-
leles in both cases and controls. We therefore performed
gene burden tests to find evidence of overrepresented rare
or common variants in individual genes or transcripts in
the cases or controls, respectively. Interestingly, we found
that the genes ADAM19, WNT2, CHRNA5, NOS3 and
PTCH1 all contain rare variants (MAF < 5 %) uniquely
found in cases of the OLIN discovery sample. These vari-
ants, and especially the coding variants with predicted
functional effect, could be followed up in a larger case–
control sample for verification and further genetic and
functional analysis.
We assessed 83 genes and 10 genomic regions of 1.5 kb
size for variants associated with COPD in a sample from
Northern Sweden. Still, one limitation of our study is that
the targeted capture design may exclude yet unknown gen-
omic regions that can harbour genetic variation influencing
COPD. Also, the two novel variants detected after sequen-
cing were monomorphic and an assessment of the false dis-
covery rate using HaloPlex with subsequent Illumina
sequencing would be helpful in order to evaluate our set of
candidate genes as a gene panel for COPD. Furthermore,
we cannot rule out that some findings are influenced by
population substructure and replication of our result in dif-
ferent populations is essential. It is also possible that some
risk variants were not identified due to the limited number
of cases and controls used for sequencing. Using a con-
servative Bonferroni correction based on the 1588 variants
detected resulted in no variants reached significant associ-
ation with COPD. However, we believe there is no definite
consensus regarding the type of multiple testing procedures
to use in targeted sequencing based approaches. Further-
more, many parameters such as variant quality checks,
genotyping success rate and sequencing depth limit will in-
fluence the number of variants found, and consequently,
multiple testing adjustments. Also, in addition to include
genes including variants previously associated with COPD
or asthma, we explored if a set of genes involved in lung de-
velopment would harbour variants in association with
COPD in the Swedish discovery sample. Therefore, as the
study is exploratory with a mixed hypothesis the p values
for association testing in this study are not corrected for
multiple testing.
Despite the limited size of the discovery sample used
here, we identified several high-risk genetic variants for
COPD and we replicated several previous GWAS results.
In particular, our results support the CHRNA5 gene as a
likely candidate gene for COPD where the rs8040868-C
allele confers a risk for the disease in the Swedish popu-
lation. Furthermore, we indicate the advantage of using
less heterogeneous populations in the studies of complex
disorders.
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